Advancements in genomic and mutational analysis show that up to 60% of adenocarcinomas and up to 50% to 80% of squamous cell carcinomas (SCC) have a known oncogenic driver mutation.
Herman W. Powery II, PharmD, BCOP
Advertisement
Articles by Herman W. Powery II, PharmD, BCOP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Evolving Mortality Trends in Heart Failure and Vascular Disease: The Critical Role of Pharmacists in Addressing Cardiovascular Risk
2
Targeting Mitochondrial Metabolism in Heart Failure: From Genetic Drivers to Fuel Modulation Therapies
3
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
4
SGLT2 Inhibitors Linked to Lower Atrial Fibrillation Risk, Recurrence
5
